statin clinical trials
Jump to navigation
Jump to search
Clinical trials
* ASCOT LLA trial, significant benefit for atorvastatin 10 mg QD
* 80 mg atorvastatin prevented more strokes & heart attacks than 10 mg atorvatation (10.3% vs 12.6%) over 5 years, but resulted in more adverse effects (8.3% vs 5.2%)
3809 patients > 65 years of age with coronary artery disease randomly assigned to receive atorvastatin 10 mg or 80 mg QD
primary outcome was 1st major cardiovascular event
Patients were followed for a median of 4.9 years[1]
More general terms
More specific terms
References
- ↑ 1.0 1.1 Wenger NK et al, Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007, 147:9 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17606955